by FiveSenses | Nov 25, 2024 | News Release
Vancouver, BC, Canada, November 25, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug... 
by FiveSenses | Nov 25, 2024 | News Release
VANCOUVER, BC, CANADA, NOVEMBER 22, 2024 – DEFENCE THERAPEUTICS INC. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug... 
by FiveSenses | Nov 14, 2024 | News Release
Vancouver, BC, Canada, November 14, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE:DTC, OTCQB: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug... 
by FiveSenses | Nov 13, 2024 | News Release
Vancouver, BC, Canada, November 13, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug... 
by FiveSenses | Nov 4, 2024 | News Release
Vancouver, BC, Canada, November 4, 2024 – Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug...
Recent Comments